Jacques R. Seguin
Chairman Of The Board @ Emanate Biomedical
London, United Kingdom
Jacques R. Seguin is a seed investor at Emanate Biomedical in London focused on Medical and Medical Device. Jacques Seguin is the Chairman Of The Board at Emanate Biomedical. He Attended Paris-Sud University (Paris XI) during 1975-1985.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Jacques R. Seguin invests in
Stages Jacques R. Seguin invests in
Countries Jacques R. Seguin invests in
Investment Focus
Industry
- Medical 3 (100%)
- Medical Device 3 (100%)
- Health Care 1 (33%)
- Health Diagnostics 1 (33%)
Stage
- Seed 1 (33%)
- Pre-Seed 1 (33%)
- Venture - Series Unknown 1 (33%)
Country
- Israel 2 (67%)
- Switzerland 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Althea Medical
|
Althea Medical is a creator of catheter devices for the treatment of patients with sub- or major pulmonary emboli. The company is developing a catheter-based solution for treating patients suffering from massive and sub-massive Pulmonary Embolism (PE). Althea Medical was established in 2020 in Tel Aviv, Israel. | $1.5M / Pre-Seed / Jun 01, 2023 | |
Pi-Cardia
|
Pi-Cardia is a medical device start-up company developing a novel low profile catheter for the treatment of aortic stenosis. The company's proprietary technology is based on delivering mechanical impact for creating fractures in valve calcifications, without injuring the surrounding soft tissue. This treatment, which only takes severalseconds, is intended to increase the valve effective orifice area without the need to replace the valve. | $27M / Venture - Series Unknown / Apr 20, 2020 | |
CorFlow Therapeutics
|
CorFlow Therapeutics is a medtech startup that develops proprietary technologies for diagnosis and treatment of microvascular obstructions in heart attack patients. The CorFlow technologies enable interventional cardiologists to diagnose and treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complicationrates in these patients. | $3M / Seed / Oct 24, 2017 |
Co-Investors
Peregrine Ventures
1 deal together
Sofinnova Partners
1 deal together
About Emanate Biomedical
Emanate Biomedical is a medical device company developing novel non-invasive treatment and maintenance therapies for oral diseases.
Emanate Biomedical Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Jacques R. Seguin
Chairman Of The Board
|
|||
4 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Jacques R. Seguin invest in?
Jacques R. Seguin invests primarily in Medical, Medical Device and Health Care startups, most often at Seed and Pre-Seed stage. Most of the 3 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Jacques R. Seguin last invest?
The most recent investment recorded for Jacques R. Seguin closed in Jun 2023. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
